SCHEMBL2230732

SCHEMBL2230732

CCCC(O)c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 5/20 0.51
KCNH2 Q12809 1/20 0.51
CYP2D6 P10635 1/20 0.49
KCNE1 P15382 1/20 0.49
KCNJ5 P48544 1/20 0.47
KCNJ3 P48549 1/20 0.47
SCN5A Q14524 1/20 0.47
KCND3 Q9UK17 1/20 0.47
CYP1A2 P05177 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
CHRM2 P08172 2/20 0.44
SCN1A P35498 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN3A Q9NY46 1/20 0.44
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30596267 1.00 KCNA5 (0.51) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL1526122 0.91 KCNA5 (0.50) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL7275282 0.91 KCNA5 (0.50) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL8986648 0.89 KCNA5 (0.49) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL7293012 0.89 KCNA5 (0.49) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL16227724 0.87 KCNA5 (0.47) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL28331181 0.87 KCNA5 (0.47) KCNA5KCNH2CYP2D6KCNE1KCNJ5
Hydrochloric Acid SCHEMBL8608055 0.87 KCNA5 (0.47) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL6000906 0.87 KCNA5 (0.47) KCNA5KCNH2CYP2D6KCNE1KCNJ5
SCHEMBL31744336 0.86 KCNA5 (0.52) KCNA5KCNH2CYP2D6KCNE1KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112724757-A Ionomer coating for eliminating surface charge, preparation method thereof and corresponding coating 徐宁 2021-04-30 CN claimed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2024-09-12 US disclosed
EP-3483143-B1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC (US) 2023-10-18 EP disclosed
EP-3483143-B1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC (US) 2023-10-18 EP disclosed
WO-2023131530-A1 A CLEANING COMPOSITION FOR METAL SUBSTRATES PRETREATMENT AND ITS PREPARATION METHOD AND APPLICATION THEREOF BASF COATINGS GMBH (DE) 2023-07-13 WO disclosed
EP-4092012-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2022-11-23 EP disclosed
EP-4092012-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2022-11-23 EP disclosed
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2022-06-02 US disclosed
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2022-06-02 US disclosed
US-20110195839-A1 Liquid Aqueous Crop Protection Formulations BASF SE (DE) 2011-08-11 US disclosed
US-20110195846-A1 Liquid Pyraclostrobin-Containing Crop Protection Formulations BASF SE (DE) 2011-08-11 US disclosed
EP-2348833-A2 LIQUID AQUEOUS CROP PROTECTION FORMULATIONS BASF SE (DE) 2011-08-03 EP disclosed
EP-2346322-A2 LIQUID PYRACLOSTROBIN-CONTAINING CROP PROTECTION FORMULATIONS BASF SE (DE) 2011-07-27 EP disclosed
WO-2010040835-A2 LIQUID PYRACLOSTROBIN-CONTAINING CROP PROTECTION FORMULATIONS BASF SE (DE) 2010-04-15 WO disclosed
WO-2010040834-A2 LIQUID AQUEOUS CROP PROTECTION FORMULATIONS BASF SE (DE) 2010-04-15 WO disclosed
CN-1201741-C Agent for prevention and treatment of ischemia reperfusion disorder CCI CORP (JP) 2005-05-18 CN disclosed
CN-1125640-C Prophylactic and therapeutic agent for inflammatory intestinal diseases CCI CORP (JP) 2003-10-29 CN disclosed
CN-1290169-A Agent for prevention and treatment of ischemia reperfusion disorder CCI CORP (JP) 2001-04-04 CN disclosed
CN-1245430-A Prophylactic and therapeutic agent for inflammatory intestinal diseases CCI CORP (JP) 2000-02-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A KCNA5 4353/4885KCNH2 4697/4885CYP2D6 2390/4885
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 KCNA5 3702/4885KCNH2 4455/4885CYP2D6 3100/4885
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A KCNA5 4353/4885KCNH2 4697/4885CYP2D6 2390/4885
US-20110195839-A1 Liquid Aqueous Crop Protection Formulations AQP1, GANC, BROX KCNA5 3061/4885KCNH2 2657/4885CYP2D6 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.